A double-blind placebo-controlled study of EPA + DHA supplementation in lung cancer patients actively undergoing chemotherapy demonstrated a significant decrease in plasma C-reactive protein (CRP) and interleukin-6 concentrations in the supplemented group after 66 days, relative to controls [17]. Here, CRP is linked to lung cancer.